Research reveals that over 15 million people in the US, UK, Germany, and France are unaware they have metabolic dysfunction-associated steatotic liver disease, a condition linked to severe health risks. Experts call for increased screenings and diagnosis rates.
A groundbreaking study shows that GLP-1 diabetes drugs may reduce the risk of obesity-related cancers by 7% compared to DPP-4 inhibitors, particularly in women. Discover the implications for diabetes treatment!
New research reveals that silencing hyperactive AgRP neurons in the brain could reverse type 2 diabetes without affecting weight or diet. This groundbreaking study challenges existing beliefs and points to new treatment avenues.
A new study reveals a concerning link between ultraprocessed foods and early signs of Parkinson’s disease. Researchers warn that our diet could play a crucial role in brain health.
New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
A new study reveals that combinations of common food additives may increase the risk of Type 2 diabetes. Researchers analyzed data from over 108,000 adults, highlighting specific additive mixtures linked to health risks.
Recent research suggests that Ozempic and similar GLP-1 drugs may lower the risk of dementia in those with type 2 diabetes. Discover how these drugs are being tested for dementia prevention!
